<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592692</url>
  </required_header>
  <id_info>
    <org_study_id>CL-SelectAte-II-01</org_study_id>
    <nct_id>NCT04592692</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip</brief_title>
  <official_title>A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip Administered Intravenously to Severe Haemophilia A Patients With and Without Inhibitors to FVIII</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascension Healthcare Development Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascension Healthcare Development Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that PEGylated liposomes (PEGLip) can shield&#xD;
      FVIII from the immune system and inhibitors, and therefore provide a prophylactic FVIII&#xD;
      replacement therapy for patients with inhibitors to FVIII.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label multicenter trial for patients with severe haemophilia A with&#xD;
      inhibitors to FVIII and without inhibitors as control. The trial consists of 4 periods:&#xD;
      Screening, Stage A, Stage B and Safety Follow-up.&#xD;
&#xD;
      After signing informed consent, patients are assessed for eligibility during a Screening&#xD;
      period lasting up to 21 days.&#xD;
&#xD;
      All eligible patients enter Stage A - Regimen estimation. The non-inhibitor patients receive&#xD;
      a single IV injection at a dose of 35 IU/kg FVIII reconstituted with Water For Injection.&#xD;
      Following a 4-day wash-out period, these patients as well as patients with inhibitors receive&#xD;
      a single IV injection of FVIII-PEGLip at a dose of 35 IU/kg FVIII + PEGLip 22 mg/kg to&#xD;
      determine the duration of haemostatic cover and therefore required injection frequency to&#xD;
      prevent bleeds.&#xD;
&#xD;
      Stage B - multiple dosing: all patients receive injections of FVIII-PEGLip for 6 weeks at a&#xD;
      frequency determined in Stage A for each individual patient.&#xD;
&#xD;
      Safety follow-up: 15 and 30 days after the last injection of FVIII-PEGLip, patients are&#xD;
      contacted for any adverse events or bleeding episodes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clotting activity based on ROTEM [single dose]</measure>
    <time_frame>7 days</time_frame>
    <description>Clotting profile of single IV injection of FVIII-PEGLip based on key ROTEM parameters (CT+CFT) determined at 0 hours (pre-injection) and at 20 min, 1, 2, 4, 8, 24, 48, 72, 96, 120, 144 and 168 hours after injection in severe Haemophilia A patients with inhibitors and in patients without inhibitors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clotting activity based on FVIII:C concentration [single dose]</measure>
    <time_frame>7 days</time_frame>
    <description>Clotting profile of single IV injection of FVIII-PEGLip based on FVIII:C plasma assay measured at 0 hours (pre-injection) and at 20 min, 1, 2, 4, 8, 24, 48, 72, 96, 120, 144 and 168 hours after injection in severe Haemophilia A patients with inhibitors and in patients without inhibitors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clotting activity based on ROTEM [multiple dose]</measure>
    <time_frame>6 weeks</time_frame>
    <description>Dynamics of blood clotting activity as quantified by key ROTEM parameters (CT+CFT) measured before and 20 minutes after each injection of FVIII-PEGLip at weeks 2, 4 and 6 of 6-week multiple dosing of FVIII-PEGLip in severe Haemophilia A patients with inhibitors and patients without inhibitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleed frequency</measure>
    <time_frame>6 weeks</time_frame>
    <description>Frequency of spontaneous bleeding episodes and average length (days) of bleeding-free periods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) of FVIII:C (FVIII-PEGLip) [single dose]</measure>
    <time_frame>7 days</time_frame>
    <description>AUC0-∞ of FVIII:C after single IV FVIII-PEGLip injection in severe Haemophilia A patients with inhibitors and in patients without inhibitors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) of FVIII:C (FVIII-WFI) [single dose]</measure>
    <time_frame>4 days</time_frame>
    <description>AUC0-∞ of FVIII:C after single IV FVIII-WFI injection in severe Haemophilia A patients without inhibitors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of FVIII:C (FVIII-PEGLip) [single dose]</measure>
    <time_frame>7 days</time_frame>
    <description>Cmax of FVIII:C after single IV FVIII-PEGLip injection in severe Haemophilia A patients with inhibitors and in patients without inhibitors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of FVIII:C (FVIII-WFI) [single dose]</measure>
    <time_frame>4 days</time_frame>
    <description>Cmax of FVIII:C after single IV FVIII-WFI injection in severe Haemophilia A patients without inhibitors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reaching maximum plasma concentration (Tmax) of FVIII:C (FVIII-PEGLip) [single dose]</measure>
    <time_frame>7 days</time_frame>
    <description>Tmax of FVIII:C after single IV FVIII-PEGLip injection in severe Haemophilia A patients with inhibitors and in patients without inhibitors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reaching maximum plasma concentration (Tmax) of FVIII:C (FVIII-WFI) [single dose]</measure>
    <time_frame>4 days</time_frame>
    <description>Tmax of FVIII:C after single IV FVIII-WFI injection in severe Haemophilia A patients with inhibitors and in patients without inhibitors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t1/2) of FVIII:C (FVIII-PEGLip) [single dose]</measure>
    <time_frame>7 days</time_frame>
    <description>T1/2 of FVIII:C after single IV FVIII-PEGLip injection in severe Haemophilia A patients with inhibitors and in patients without inhibitors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t1/2) of FVIII:C (FVIII-WFI)</measure>
    <time_frame>4 days</time_frame>
    <description>T1/2 of FVIII:C after single IV FVIII-WFI injection in severe Haemophilia A patients without inhibitors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhibitor titres</measure>
    <time_frame>Approximately 12 weeks</time_frame>
    <description>Individual changes of inhibitor titres from baseline measurement to 168 hours after single IV injection of FVIII-PEGLip and at weeks 2, 4, and 6 of 6-week FVIII-PEGLip multiple dosing period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of PEGLip [single dose]</measure>
    <time_frame>7 days</time_frame>
    <description>AUC0-∞ of PEGLip determined at 0 hours (pre-injection) and at 20 min, 1, 2, 4, 8, 24, 48, 72, 96, 120, 144 and 168 hours after single IV injection of FVIII-PEGLip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of PEGLip [single dose]</measure>
    <time_frame>7 days</time_frame>
    <description>Cmax of PEGLip determined at 0 hours (pre-injection) and at 20 min, 1, 2, 4, 8, 24, 48, 72, 96, 120, 144 and 168 hours after single IV injection of FVIII-PEGLip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reaching maximum plasma concentration (Tmax) of PEGLip [single dose]</measure>
    <time_frame>7 days</time_frame>
    <description>Tmax of PEGLip determined at 0 hours (pre-injection) and at 20 min, 1, 2, 4, 8, 24, 48, 72, 96, 120, 144 and 168 hours after single IV injection of FVIII-PEGLip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of PEGLip [single dose]</measure>
    <time_frame>7 days</time_frame>
    <description>t1/2 of PEGLip determined at 0 hours (pre-injection) and at 20 min, 1, 2, 4, 8, 24, 48, 72, 96, 120, 144 and 168 hours after single IV injection of FVIII-PEGLip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEGLip concentration [multiple dose]</measure>
    <time_frame>6 weeks</time_frame>
    <description>PEGLip concentration measured before and 20 minutes after each injection of FVIII-PEGLip at weeks 2, 4 and 6 of 6-week multiple dosing of FVIII-PEGLip</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Approximately 12 weeks</time_frame>
    <description>Adverse events / Serious Adverse Events developed in the course of the study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hemophilia A With Inhibitor</condition>
  <arm_group>
    <arm_group_label>Inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with inhibitors to FVIII</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-inhibitors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients without inhibitors to FVIII</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEGylated Liposome (PEGLip)</intervention_name>
    <description>Intravenous co-administration of PEGLip with Simoctocog alfa</description>
    <arm_group_label>Inhibitors</arm_group_label>
    <arm_group_label>Non-inhibitors</arm_group_label>
    <other_name>Simoctocog alfa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male adult patients aged 18 to 60 years;&#xD;
&#xD;
          -  Severe Haemophilia A (FVIII plasma level &lt;1IU/dL) with documented history of bleeds&#xD;
             (for at least 6 months prior to enrolment);&#xD;
&#xD;
          -  For patients without inhibitors: inhibitor titre &lt; 0,6 Bethesda units and no medi-cal&#xD;
             history of inhibitors;&#xD;
&#xD;
          -  For patients with inhibitors: inhibitor titre ≥0,6 Bethesda units or documented&#xD;
             medical history of inhibitors titre ≥0,6 Bethesda units;&#xD;
&#xD;
          -  Adequate hematologic function, defined as platelet count ≥ 100,000/μL and hemoglobin ≥&#xD;
             8 g/dL (≥ 4.97 mmol/L) at the time of screening;&#xD;
&#xD;
          -  Adequate hepatic function, defined as total bilirubin ≤ 1.5 × the upper limit of&#xD;
             normal (ULN) (excluding Gilbert's syndrome) and aspartate aminotransferase (AST) and&#xD;
             alanine aminotransferase (ALT) ≤ 3 ×ULN at the time of screening; no clinical signs or&#xD;
             known laboratory/radiographic evidence consistent with cirrho-sis;&#xD;
&#xD;
          -  Adequate renal function, defined as serum creatinine ≤ 2.5 × ULN and creati-nine&#xD;
             clearance by Cockcroft-Gault formula ≥ 30 mL/min;&#xD;
&#xD;
          -  Patient's written informed consent, confirming his willingness to comply with the&#xD;
             requirements of this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Low platelet counts (&lt;100000 / μl);&#xD;
&#xD;
          -  Congenital or acquired bleeding defects (including acquired hemophilia) other than&#xD;
             Hemophilia A;&#xD;
&#xD;
          -  Abnormal renal function (serum creatinine concentrations greater than 1.3 mg/dL);&#xD;
&#xD;
          -  Active hepatic disease (persistent aspartate aminotransferase [AST] or alanine&#xD;
             aminotransferase [ALT] increases to greater than five times the upper limit of&#xD;
             normal);&#xD;
&#xD;
          -  A history of severe adverse reactions to blood products and/or plasma derived FVIII&#xD;
             concentrates or liposomes, or PEG, or Nuwiq;&#xD;
&#xD;
          -  A history of allergic reactions to bypassing agents;&#xD;
&#xD;
          -  Any concomitant immunological disease (e.g. autoimmune chronic active hepati-tis,&#xD;
             autoimmune thrombocytopenic purpura or Immune Thrombocytopenic Pur-pura (ITP), lupus,&#xD;
             Multiple Sclerosis (MS));&#xD;
&#xD;
          -  Patients receiving immunosuppressive treatment (excluding glucocorticoids);&#xD;
&#xD;
          -  Patients receiving therapy with interferon;&#xD;
&#xD;
          -  Patients receiving any immune tolerance induction (ITI) therapy at the moment of the&#xD;
             screening;&#xD;
&#xD;
          -  Any individual with known dyslipidemia disease or actively taking cholesterol lowering&#xD;
             drugs for the treatment of hypercholesterolemia or hyperlipidemia (e.g., statins,&#xD;
             cholesterol absorption inhibitors, bile acid sequestrates, nicotinic acid or&#xD;
             fibrates);&#xD;
&#xD;
          -  Intake of NSAIDs (except COX-2 inhibitors), acetylsalicylic acid (Aspirin) or any&#xD;
             other antiplatelet agents, opioids.;&#xD;
&#xD;
          -  Patients who have participated in another Clinical Trial (including medical device&#xD;
             studies) within the past 60 days;&#xD;
&#xD;
          -  Concurrent disease, treatment, or abnormality in clinical laboratory tests that could&#xD;
             interfere with the conduct of the study or that would, in the opinion of the&#xD;
             investigator or Sponsor, preclude the patient's safe participation in and completion&#xD;
             of the study or interpretation of the study results, according to the Investigator.&#xD;
&#xD;
          -  For patients without inhibitors - a history of demonstrating long half-lives for&#xD;
             FVIII.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male patients only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Yurdakul</last_name>
    <role>Study Director</role>
    <affiliation>Ascension Healthcare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sam Yurdakul</last_name>
    <phone>+44(0)2072915400</phone>
    <email>sam.yurdakul@ascension.co.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kemerovo District Clinical Hospital</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kosinova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kirov Scientific Research Institute of Hematology and Blood Transfusion</name>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timofeeva</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical Research Centre of Hematology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zozulia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novosibirsk State Medical University, Novosibirsk City Haematology Center</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pospelova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samara State Medical University</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurtov</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia A</keyword>
  <keyword>Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

